STOCK TITAN
  1. Home
  2. News
  3. GUTS

Fractyl Health Stock Price, News & Analysis

GUTS Nasdaq

Welcome to our dedicated page for Fractyl Health news (Ticker: GUTS), a resource for investors and traders seeking the latest updates and insights on Fractyl Health stock.

Fractyl Health (NASDAQ: GUTS) is a clinical-stage biotechnology company developing novel therapies targeting the root causes of obesity and type 2 diabetes. This page provides investors and healthcare professionals with timely updates on the company’s progress, including clinical trial results, regulatory milestones, and strategic initiatives.

Key resources include: Press releases detailing advancements in the Revita® duodenal resurfacing procedure, updates on the Rejuva® gene therapy platform, and analyses of pivotal studies like REMAIN-1. Track FDA designations, partnership announcements, and scientific publications demonstrating the company’s unique approach to metabolic disease modification.

All content is rigorously sourced from official company communications and regulatory filings. Bookmark this page to stay informed about Fractyl Health’s progress in developing durable alternatives to chronic medications through its innovative procedural and gene therapy platforms.

News

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Rhea-AI Summary
Fractyl Health (NASDAQ: GUTS) reported promising 3-month data from the REVEAL-1 Cohort of its REMAIN-1 pivotal study for Revita, a potential first-in-class weight maintenance therapy. The study showed that 12 out of 13 participants maintained or lost weight after discontinuing GLP-1 therapy and receiving the Revita procedure, with 6 participants achieving additional weight loss. The median weight remained stable with only a 0.46% change (approximately 1 pound), compared to the typical 5-6% weight regain observed after stopping GLP-1 therapy. The treatment demonstrated excellent tolerability with only mild, transient adverse effects. The study included participants who had previously lost at least 15% of their total body weight on GLP-1 therapy, with a median total body weight loss of 20.9%. The company expects Midpoint Cohort data in Q3 2025 and Pivotal Cohort data in H2 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.77%
Tags
none
-
News

Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

Rhea-AI Summary
Fractyl Health (NASDAQ: GUTS) presented promising preclinical data for its Rejuva Smart GLP-1 pancreatic gene therapy platform at ADA's 85th Scientific Sessions. The study demonstrated that a single dose of Rejuva prevented obesity and type 2 diabetes in mice exposed to high-fat diets, showing a 20% reduction in body weight and 38% decrease in blood glucose by day 21. The therapy's unique mechanism enables nutrient-responsive secretion, activating only under metabolic stress while remaining inactive in healthy conditions. The treatment was well-tolerated with no toxicity signs. Fractyl expects to begin human trials with its first clinical candidate RJVA-001 and report preliminary data in 2026, positioning it as a potential first-in-class gene therapy for metabolic control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.77%
Tags
none
-
News

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Rhea-AI Summary
Fractyl Health (NASDAQ: GUTS) has strengthened its intellectual property portfolio with two new U.S. patents focused on duodenal resurfacing technology for treating metabolic diseases. The patents (No. 12,329,439 and No. 12,303,185) cover ablation of duodenal mucosa using thermal and non-thermal electrical energy. The company's IP portfolio now includes 31 granted U.S. patents and approximately 40 pending U.S. applications. Fractyl's Revita® treatment represents a first-in-class therapy for obesity and type 2 diabetes, with clinical data from hundreds of treated patients. The company anticipates three key data readouts: REVEAL-1 Cohort open-label data in June 2025, REMAIN-1 Midpoint Cohort data in Q3 2025, and REMAIN-1 Pivotal Cohort 6-month primary endpoint data in H2 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
none
News

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Rhea-AI Summary
Fractyl Health (NASDAQ: GUTS), a metabolic therapeutics company, will present new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association's 85th Scientific Sessions. The presentation, scheduled for June 22, 2025, will showcase results from a study titled 'Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice.' The poster session will take place at the ADA conference in Chicago from June 20-23, 2025, with the specific presentation scheduled for 12:30-1:30 PM in Hall F1. The data will be made available on Fractyl's website after the conference presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.07%
Tags
conferences clinical trial
-
News

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

Rhea-AI Summary
Fractyl Health (NASDAQ: GUTS) and Bariendo have signed a Letter of Intent to explore collaboration for implementing Fractyl's investigational Revita procedure across Bariendo's nationwide bariatric and metabolic endoscopy centers. Revita, pending FDA approval, is being developed as a potential solution for weight maintenance after GLP-1 drug discontinuation. The outpatient endoscopic procedure targets the duodenal lining to address root causes of obesity. Three key data readouts are expected: REVEAL-1 Cohort data in June 2025, REMAIN-1 Midpoint Cohort data in Q3 2025, and REMAIN-1 Pivotal Cohort primary endpoint data in H2 2026. The collaboration aims to develop operational readiness for Revita's integration into clinical offerings, focusing on workflow design, provider education, and health economic analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
-
News

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

Rhea-AI Summary
Fractyl Health (NASDAQ: GUTS) has submitted the first module of its Clinical Trial Application (CTA) in Europe for RJVA-001, a novel gene therapy candidate targeting type 2 diabetes and obesity. RJVA-001 is designed to express GLP-1 locally in pancreatic beta cells using nutrient-responsive control, delivered through a one-time, minimally invasive endoscopic procedure. The therapy aims to enable physiologic hormone secretion without the high circulating levels associated with side effects in traditional GLP-1 drugs. Recent preclinical data presented at ASGCT 2025 demonstrated safety and dose-dependent potency. Pending regulatory approval, Fractyl expects to begin first-in-human dosing and report preliminary data in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.44%
Tags
clinical trial
News

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

Rhea-AI Summary
Fractyl Health (NASDAQ: GUTS) presented promising preclinical data for RJVA-001, its Rejuva® Smart GLP-1™ pancreatic gene therapy platform, at ASGCT 2025. The data showed that a single dose of RJVA-001 achieved durable metabolic improvements in diabetic mice, including a >200 mg/dL reduction in fasting blood sugar and prevention of weight gain. Notably, RJVA-001 demonstrated 5-fold lower systemic GLP-1 exposure compared to current GLP-1 drugs, suggesting reduced side effects. The therapy showed targeted pancreatic expression through endoscopic ultrasound-guided delivery in large animal studies, with no observed toxicity. The platform demonstrated nutrient-responsive GLP-1 secretion, mimicking natural hormone regulation. Fractyl Health plans to submit its first CTA module for RJVA-001 by June 2025, with preliminary human data expected in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

Rhea-AI Summary
Fractyl Health (NASDAQ: GUTS) reported Q1 2025 financial results and provided updates on its metabolic therapeutics programs. The company's key focus is on maintaining weight loss after GLP-1 therapy discontinuation. Key highlights include: - REVEAL-1 Cohort showed promising early results with only 1.2% weight regain vs typical 3% after GLP-1 discontinuation - REMAIN-1 Midpoint Cohort (45 participants) completed enrollment, with data expected in Q3 2025 - REMAIN-1 Pivotal Cohort (315 participants) completed enrollment ahead of schedule - Rejuva gene therapy platform advancing with first CTA module submission planned for June 2025 Financial results show R&D expenses of $19.4M (up from $14.4M in Q1 2024), net loss of $23.7M (vs $3.3M in Q1 2024), and cash position of $42.1M, expected to fund operations into Q4 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.28%
Tags
earnings
-
News

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Rhea-AI Summary

Fractyl Health (NASDAQ: GUTS), a metabolic therapeutics company specializing in treatments for obesity and type 2 diabetes, has scheduled two important investor events. The company will release its Q1 2025 financial results and provide business updates on May 13, 2025, at 4:30 p.m. ET via a live webcast.

Additionally, CEO and Co-Founder Harith Rajagopalan, M.D., Ph.D., will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 5:00 p.m. PT. Both events will be accessible through the company's investor relations website, with recordings available for replay after the live presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.98%
Tags
conferences earnings
News

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Rhea-AI Summary

Fractyl Health (Nasdaq: GUTS) announced an upcoming presentation of preclinical data for their innovative Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting in New Orleans.

Key highlights:

  • The presentation focuses on a single-administration therapy targeting obesity and type 2 diabetes root causes
  • Research title: "Endoscopic Ultrasound-Guided Delivery of Human Glucagon-like Peptide-1 Pancreatic Gene Therapy: Safety and Feasibility in a Porcine Model"
  • Scheduled for May 17, 2025, at 9:15 AM CT in NOLA Theater A
  • Part of the AAV Preclinical and Proof-of-Concept Studies session

The presentation materials will be accessible through the Presentations & Publications section of Fractyl's website after the event concludes on May 17, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
conferences clinical trial

FAQ

What is the current stock price of Fractyl Health (GUTS)?

The current stock price of Fractyl Health (GUTS) is $1.82 as of July 29, 2025.

What is the market cap of Fractyl Health (GUTS)?

The market cap of Fractyl Health (GUTS) is approximately 94.0M.
Stock GUTS logo
Fractyl Health

Nasdaq:GUTS

GUTS Rankings

#7359 Ranked by Market Cap
N/A Ranked by Dividends

GUTS Stock Data

94.04M
46.51M
4.73%
83.33%
6.2%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States
BURLINGTON